Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

被引：11

作者：

Gentile, Massimo ^{[1
]}

Shanafelt, Tait D. ^{[2
]}

Mauro, Francesca Romana ^{[3
]}

Reda, Gianluigi ^{[4
]}

Rossi, Davide ^{[5
]}

Laurenti, Luca ^{[6
]}

Del Principe, Maria Ilaria ^{[7
]}

Cutrona, Giovanna ^{[8
]}

Angeletti, Ilaria ^{[9
]}

Coscia, Marta ^{[10
]}

Herishanu, Yair ^{[11
,12
]}

Chiarenza, Annalisa ^{[13
]}

Molica, Stefano ^{[14
]}

Ciolli, Stefania ^{[15
]}

Goldschmidt, Neta ^{[16
]}

Angrilli, Francesco ^{[17
]}

Giordano, Annamaria ^{[18
]}

Rago, Angela ^{[19
]}

Bairey, Osnat ^{[20
,21
]}

Tripepi, Giovanni ^{[22
]}

Chaffee, Kari G. ^{[23
]}

Sameer, Parikh A. ^{[24
]}

Vigna, Ernesto ^{[1
]}

Zirlik, Katja ^{[25
]}

Shvidel, Lev ^{[26
,27
,28
]}

Innocenti, Idanna

Recchia, Anna Grazia ^{[29
]}

Di Raimondo, Francesco ^{[13
]}

Del Poeta, Giovanni ^{[7
]}

Cortelezzi, Agostino ^{[4
]}

Neri, Antonino ^{[4
]}

Ferrarini, Manlio ^{[30
]}

Gaidano, Gianluca ^{[31
]}

Kay, Neil E. ^{[2
]}

Polliack, Aaron ^{[16
]}

Foa, Robin ^{[3
]}

Morabito, Fortunato ^{[29
]}

机构：

[1] Osped Annunziata, UOC Ematol, Cosenza, Italy

[2] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA

[3] Univ Sapienza, Ematol, Rome, Italy

[4] Univ Milan, Osped Maggiore Policlin, Fdn Ca Granda IRCCS, Unita Ematol, Milan, Italy

[5] Oncol Inst Southern Switzerland, Inst Oncol Res, Bellinzona, Switzerland

[6] Univ Cattolica A Gemelli Rome, Dipartimento Ematol, Rome, Italy

[7] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenzione, Ematol, Rome, Italy

[8] IRCCS S Martino IST, UOC Patol Mol, Genoa, Italy

[9] Azienda Osped Santa Maria Tern, Reparto Oncoematol, Terni, Italy

[10] Univ Torino, AO Citta Salute & Sci Torino, Div Ematol, Turin, Italy

[11] Tel Aviv Univ, Tel Aviv Sourasky Med, Dept Hematol, Tel Aviv, Israel

[12] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[13] Univ Catania, Osped Ferrarotto, Div Ematol, Catania, Italy

[14] Azienda Osped Pugliese Ciaccio, Dipartimento Oncoematol, Catanzaro, Italy

[15] Univ Firenze, Ematol, Florence, Italy

[16] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel

[17] Osped Spirito Santo, Dipartmento Ematol, Pescara, Italy

[18] Ematol Azienda Osped Univ, Policlin Consorziale Bari, Bari, Italy

[19] Osped Santa Maria Goretti, UOC Ematol, Latina, Italy

[20] Rabin Med Ctr, Dept Hematol, Petah Tiqwa, Israel

[21] Tel Aviv Univ, Sackler Fac Med, Petah Tiqwa, Israel

[22] CNR, Ist Biomed & Immunol Mol, Reggio Di Calabria, Italy

[23] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA

[24] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA

[25] Univ Med Ctr Freiburg, Dept Haematol & Oncol, Freiburg, Germany

[26] Kaplan Med Ctr, Dept Hematol, Rehovot, Israel

[27] Hadassah Med Ctr, Jerusalem, Israel

[28] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[29] Azienda Sanit Provinciale Cosenza, Unita Ric Biotecnol, Aprigliano, CS, Italy

[30] Direzione Sci IRCCS, San Martino IST, Genoa, Italy

[31] UPO, Dept Translat Med, Div Haematol, Novara, Italy

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2018年 / 101卷 / 05期

关键词：

chemo-immunotherapy; chronic lymphocytic leukemia; CLL-IPI; PFS; prognosis; progression-free survival; CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY UNTREATED PATIENTS; PROGNOSTIC INDEX; RITUXIMAB; CYCLOPHOSPHAMIDE; BENDAMUSTINE; FLUDARABINE; TRIAL; COMBINATION; MULTICENTER;

D O I：

10.1111/ejh.13149

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：703 / 706

页数：4

共 50 条

[31] Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy
Perrone, A. Leonetti F.
Puntoni, M.
Bordi, P.
Maglietta, G.
Carpana, C.
Gelsomino, F.
Passiglia, F.
Genova, C.
Montrone, M.
Caliman, E.
Cerea, G.
Pasello, G.
Cecere, F.
Manzo, A.
Adamo, V.
Citarella, F.
Toschi, L.
Gelibter, A.
Rastelli, F.
Carta, A.
Guida, A.
Camerini, A.
Paoloni, F.
Bertolini, F.
Tiseo, M.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S338 - S339
[32] First-line treatment and outcome in patients with chronic lymphocytic leukemia (CLL) according to age: a report of the German CLL Study Group (GCLLSG) registry
Maurer, C.
Fink, A. M.
Robrecht, S.
Bahlo, J.
Fischer, K.
Eichhorst, B.
Hallek, M.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 170 - 171
[33] Determining first-line CLL/SLL treatment strategies with optimized efficacy and safety
Mehta, Amitkumar
[J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (SUPPL 2) : S14 - S19
[34] Salvage therapy following failure or relapse after FCR chemo-immunotherapy as initial treatment for chronic lymphocytic leukemia (CLL)
Keating, M. J.
Wierda, W.
O'Brien, S.
Tam, C.
Lerner, S.
Kantarjian, H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[35] Fludarabine, cyclophosphamide and rituximab (FCR) first-line therapy in CLL patients: an analysis of the registry of the German CLL Study Group
Fink, A. M.
Federhen, A.
Kutsch, N.
Stumpf, J.
Giza, A.
Robrecht, S.
Stoltefuss, A.
Vehling-Kaiser, U.
Koenigsmann, M.
Tausch, E.
Schneider, C.
Stilgenbauer, S.
Illmer, T.
Schlag, R.
Doerfel, S.
Gaska, T.
Kiehl, M.
Fischer, K.
Eichhorst, B.
Hallek, M.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 119 - 120
[36] Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis
Molica, Stefano
Giannarelli, Diana
Mirabelli, Rosanna
Levato, Luciano
Shanafelt, Tait D.
[J]. ANNALS OF HEMATOLOGY, 2018, 97 (10) : 2005 - 2008
[37] Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis
Stefano Molica
Diana Giannarelli
Rosanna Mirabelli
Luciano Levato
Tait D. Shanafelt
[J]. Annals of Hematology, 2018, 97 : 2005 - 2008
[38] Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL
Shanafelt, Tait
Tun, Han
Hanson, Curtis
Zent, Clive S.
Leis, Jose
Call, Timothy
LaPlant, Betsy
Bowen, Deborah
Laumann, Kristina
Jelinek, Diane F.
Kay, Neil E.
[J]. BLOOD, 2010, 116 (21) : 593 - 593
[39] Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect VR CLL cohort study
Flowers, Christopher R.
Nabhan, Chadi
Kay, Neil E.
Mato, Anthony
Lamanna, Nicole
Farber, Charles M.
Davids, Matthew S.
Kiselev, Pavel
Swern, Arlene S.
Sullivan, Kristen
Flick, E. Dawn
Sharman, Jeff P.
[J]. LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2327 - 2335
[40] FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE STUDY
Ionita, H.
Ionita, I.
Cheveresan, M.
Ionita, M.
Calamar, D.
Ionita, C. O.
Oros, D.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 526 - 526

← 1 2 3 4 5 →